Quick Answer: What is PMOS?
Polycystic ovary syndrome (PCOS) has a new name: Polyendocrine Metabolic Ovarian Syndrome, or PMOS. The name change reflects a broader understanding of a condition that involves endocrine, metabolic, and ovarian features — not ovarian “cysts” alone.
Key Takeaways:
- PMOS is the updated name for PCOS.
- PMOS and PCOS refer to the same condition.
- The name change does not automatically change diagnostic criteria or a patient’s care plan.
- The new term better reflects endocrine, metabolic, and ovarian features.
- Compounding may support provider-directed prescriptions when a patient needs a specific dosage form, strength, or ingredient profile.
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for Polycystic Ovary Syndrome (PCOS). The Lancet published the name change after a global consensus process involving 56 academic, clinical, and patient organizations. This update isn’t a simple rebranding. It’s a correction that reflects what decades of research now confirm about a condition long described through a narrow lens.
The updated name better reflects the endocrine, metabolic, and ovarian features that may be involved. It also recognizes that the condition can look very different from patient to patient, a reason why more precise terminology matters.
Because PMOS affects an estimated 1 in 8 women or more than 170 million women worldwide, patients, prescribers, and pharmacists all benefit from language that describes the condition more accurately.
The name breaks down into four meaningful parts:
- Polyendocrine points to the involvement of more than one hormonal system. It includes neuroendocrine, metabolic, and ovarian pathways.
- Metabolic recognizes insulin resistance and cardiovascular health.
- Ovarian keeps ovarian function in the name, acknowledging its role while no longer making it the sole focus.
- Syndrome signals that the condition may involve a group of related signs, symptoms, and health patterns rather than a single defining feature.
With this wider view, symptoms that once felt disconnected become easier to name, connect, and manage together.
At Central Ohio Compounding Pharmacy, we see this shift as an opportunity for clearer care planning. Central Ohio patients, prescribers, and pharmacists can use this updated language to talk more directly about endocrine health, metabolic health, and individualized medication needs.
“Global effort changes the name of a significant women’s health condition that was misunderstood to be ‘all about ovarian cysts.’”
To understand why the new name matters, it helps to look at what the old name got wrong.
Why PCOS Was Renamed to PMOS
The old name placed too much attention on “polycystic ovaries.” For many patients, the word cysts created confusion because the ovarian findings associated with this condition are not the same as the painful, pathological ovarian cysts many people imagine.
Instead, imaging often shows immature follicles, a normal ovarian structure that was misidentified when the condition was first described nearly a century ago. PMOS corrects that narrow framing by recognizing a broader pattern of hormone, metabolic, skin, cycle, and long-term health concerns that the old name routinely obscured.
Next, the new terminology may help patients, prescribers, and pharmacists discuss the condition more clearly.
What the PMOS Name Change Means for Patients
For patients, the PMOS name change can make symptoms easier to place in context. Irregular periods, acne, excess facial or body hair, and metabolic concerns are no longer disconnected issues; they belong to the same clinical picture. The “cyst language” also becomes easier to clarify because painful or abnormal ovarian cysts do not define PMOS.
What the PMOS Name Change Means for Prescribers and Pharmacists
For prescribers, PMOS gives clearer language for explaining why metabolic health belongs in the evaluation. Insulin resistance, metabolic syndrome risk, and long-term screening are appropriate topics for a wider range of patients than the old name implied.
For pharmacists, the updated terminology provides better context for compounding questions. Dosage form, patient-specific strength, and inactive ingredient considerations all depend on understanding the full clinical picture.
That broader language matters most when metabolic health enters the conversation.
Why Metabolic Health Belongs in the PMOS Conversation
PMOS and PCOS refer to the same condition, but the updated name brings its endocrine and metabolic features into the foreground where they belong. Research shows that insulin resistance affects approximately 60–75% of women with this condition.
In addition, metabolic syndrome prevalence reaches up to 56% in some study populations. Clinicians often underscreened these findings because the older name pointed attention elsewhere.
In PMOS care discussions, metabolic factors that may be relevant include:
- Insulin resistance and blood sugar concerns, including elevated type 2 diabetes risk
- Blood pressure and cholesterol concerns, including hypertension, dyslipidemia, or elevated triglycerides
- Cardiometabolic and liver-related concerns, including cardiovascular risk, metabolic dysfunction-associated liver disease, and long-term metabolic syndrome screening
Although less visible than acne or cycle changes, these features can significantly influence the direction of care.
For patients, this can raise more specific questions about blood sugar, cholesterol, blood pressure, and long-term metabolic monitoring.
For prescribers, these factors bear on lab review, follow-up intervals, and medication decisions.
When a standard medication does not align with a patient’s needs, a provider may consider whether a custom strength, different dosage form, or simpler ingredient profile would be more appropriate.
How the PCOS-to-PMOS Name Change Happened
The Lancet published the name change following a global consensus process. Researchers gathered survey responses from more than 14,000 people with PCOS and multidisciplinary health professionals across all regions.
The consensus process established several practically important points, including:
- PMOS is the new name for the condition previously known as PCOS.
- PMOS more accurately reflects endocrine, metabolic, and ovarian features, omitting the misleading reference to cysts and capturing the condition’s multisystem nature.
- The transition is already underway. Health systems, research institutions, guideline groups, and disease classification systems are updating terminology over a planned three-year transition period.
- Prescribers will continue to see PCOS referenced in older records and orders during this time. However, PMOS is the updated term for the same condition.
For providers, that last point matters: the name change does not alter diagnostic criteria or therapy frameworks currently in use. It aligns the language with science.
How PMOS Name Change Can Support Medication Discussions
PMOS does not point to a single universal medication path. Instead, it gives prescribers a more complete foundation for considering the patient’s full picture. This matters because patient-specific care often shows up in the prescription details.
When a prescriber determines that customization is appropriate, a compounding pharmacy may prepare the medication according to specific clinical needs, including:
- Dosage form: A prescribed form that may better align with the patient’s routine, preferences, or tolerability needs.
- Specific strength: A patient-specific dose based on the provider’s assessment, care goals, and management plan.
- Ingredient profile: A formulation that removes certain dyes, preservatives, fillers, or other excipients when a patient has a sensitivity, allergy, or tolerability concern.
At Central Ohio Compounding Pharmacy, our pharmacists work with prescribers in Worthington, Columbus, and across Central Ohio to support specific prescribing needs. For PMOS-related care, that means helping translate individualized clinical decisions into prepared, customized prescriptions when appropriate.
Compounded medications are not FDA-approved. The FDA does not review compounded medications for safety, effectiveness, or quality before they are dispensed. Compounded medications are prepared based on individual patient needs and require a prescription from a licensed provider.
Personalized Women’s Health Compounding Pharmacy in Central Ohio
Central Ohio Compounding Pharmacy has supported personalized compounding care since 1997. From our Worthington and Columbus locations, we work with patients and prescribers across Central Ohio when a prescription needs to be prepared around specific patient needs.
For women’s health and PMOS-related care, our role is to support the medication details behind the prescriber’s plan. That may include preparing a prescribed dosage form, patient-specific strength, or ingredient-conscious formulation when the provider determines customization is appropriate.
We also support prescribers with formulation questions through our Provider Resources. That collaboration helps translate individualized care decisions into clear, prepared prescriptions.
If you have questions about whether compounding may fit a specific prescription need, our pharmacy team is here to help guide the next step.
Questions to Ask Your Provider or Pharmacist About PMOS
If you were diagnosed with PCOS or are now seeing the term PMOS, it may help to bring specific questions to your provider or pharmacist.
You may want to ask:
- Does PMOS change how we discuss my condition or my care goals?
- Should insulin resistance, blood sugar, cholesterol, blood pressure, or metabolic syndrome screening be part of my evaluation?
- Does my current medication plan still fit my symptoms, goals, and daily routine?
- Could side effects, dosage form, strength, or inactive ingredients be affecting how consistently I can take my medication?
- If my prescription needs customization, would a compounded option be appropriate?
These questions may help make the conversation more focused.
The preparation is dispensed using applicators designed to deliver a consistent, measured volume.
Decisions to prescribe a medication beyond its labeled use are made by licensed healthcare providers using their clinical judgment.
Schedule a Private Hormone Consultation
Lucy Andrews, PharmD
Please schedule a virtual or in-person consultation with our hormone specialist, Lucy Andrews, PharmD.
We also offer educational resources to support informed, evidence-based care.
Personalized Prescription Support in Central Ohio
If a PMOS-related care conversation leads to a prescription that needs a specific form, strength, or ingredient profile, Central Ohio Compounding Pharmacy may prepare it according to the provider’s prescription and patient-specific needs.
From our Worthington and Columbus pharmacies, our pharmacists support patients and prescribers across Ohio with customized compounding care. Contact our team for help understanding how compounding works, what information your prescriber may need, or how to begin a provider-guided compounded prescription. Shipping to Ohio patients statewide.
Frequently Asked Questions About PMOS, PCOS, and Metabolic Syndrome
What is PMOS?
PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It is the updated name for the condition previously known as PCOS or Polycystic Ovary Syndrome. The name better reflects the endocrine, metabolic, and ovarian features that may be involved.
Is PMOS the same as polycystic ovary syndrome?
Yes. PMOS and polycystic ovary syndrome refer to the same condition. The updated name does not mean every patient has a new diagnosis or a completely different care plan. It gives patients, prescribers, and pharmacists more accurate language for discussing the condition.
Why was polycystic ovary syndrome renamed PMOS?
Polycystic ovary syndrome placed too much attention on “polycystic ovaries” and the word “cysts.” PMOS removes that confusion and better reflects the condition’s wider endocrine, metabolic, and ovarian features.
Is PMOS an endocrine metabolic disorder?
Patients and providers may discuss PMOS as an endocrine-metabolic disorder because hormone-related and metabolic pathways may both be involved. These may include androgen activity, ovulation patterns, insulin resistance, blood sugar, cholesterol, blood pressure, and long-term metabolic health.
Is it polycystic ovary syndrome or metabolic syndrome?
It is not an either/or question. Polycystic ovary syndrome, now called PMOS, is a distinct condition. Metabolic syndrome is a separate group of cardiometabolic risk factors that may include blood sugar, blood pressure, cholesterol, triglycerides, and waist circumference. However, metabolic syndrome risk may be part of the PMOS care conversation for some patients.
What is the connection between metabolic syndrome and polycystic ovaries?
The phrase “metabolic syndrome and polycystic ovaries” can be confusing because PMOS is not defined by ovarian cysts alone. Some patients may have ovarian features, metabolic concerns, or both. A provider may discuss insulin resistance, cholesterol, blood pressure, blood sugar, cycle changes, skin and hair symptoms, and other hormone-related patterns as part of the larger picture.
Can a compounding pharmacy help with PMOS-related medication needs?
Yes, a compounding pharmacy may support a provider-guided PMOS care plan when a prescription requires customization. That may include a specific dosage form, patient-specific strength, or ingredient-conscious formulation. Compounded medications require a prescription from a licensed provider.
Can Central Ohio Compounding Pharmacy help with PMOS-related prescriptions in Columbus or Worthington?
Yes. Central Ohio Compounding Pharmacy supports patients and prescribers in Worthington, Columbus, and across Central Ohio when a provider determines that a prescription requires a specific dosage form, patient-specific strength, or ingredient-conscious formulation. Compounded medications require a prescription from a licensed provider.
References
- American Society for Reproductive Medicine. (2026, May 27). PCOS is now PMOS: Understanding the name change. Link
- Endocrine Society. (2026, May 12). Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide. Endocrine Society. Link
- Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., & Piltonen, T. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet, 407(10545), 2329–2339. Link